Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as oral tablets for oral use. It is used to prevent malaria infection and to treat acute uncomplicated malaria caused by Plasmodium falciparum in adults and children weighing at least 5 kg. The combination exploits two mechanisms that together provide synergistic parasite killing, making it a preferred option for travelers to endemic regions and for patients requiring prompt treatment.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial drug that acts on Plasmodium parasites to prevent and treat infection. - Malaria prophylaxis: prevents infection in travelers to endemic regions when taken before, during, and after exposure. - Acute uncomplicated P. falciparum malaria: treats infection by rapidly reducing parasite load. - Relapse prevention: used to clear residual parasites after initial therapy in certain cases.

Malarone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: occasional tension‑type headache. - Abdominal pain: discomfort in the stomach area. - Vomiting: occasional episodes after dosing. - Loss of appetite: reduced desire to eat. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: signs of liver dysfunction including jaundice. - Hematologic abnormalities: severe neutropenia or anemia. - Hypersensitivity: anaphylactic reactions requiring immediate medical attention. - Visual disturbances: rare cases of blurred vision or eye pain.

Before prescribing Malarone, clinicians should consider several safety factors. - Assess renal function: adjust use in patients with severe renal impairment. - Screen for G6PD deficiency: consider risk of hemolysis in deficient individuals. - Evaluate hepatic status: monitor liver enzymes during therapy. - Check for hypersensitivity: avoid in patients with known allergy to either component. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Malarone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations. - Protease inhibitors (e.g., ritonavir): may increase toxicity risk. - Cimetidine: can raise atovaquone levels, leading to adverse effects.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption of atovaquone. - Warfarin: potential enhancement of anticoagulant effect. - Macrolide antibiotics (e.g., erythromycin): may increase proguanil concentrations.